Mike Stathis Positioned Investors into 1500% Gains With Moderna (MRNA) in Just Over a Year

Back in March 2020, not long after the coronavirus pandemic was declared, Mike Stathis of AVA Investment Analytics held two special webinars to discuss investment ideas. Although he was bullish on the drug and biopharma stocks, he pointed out that the big winners would be smaller companies that would be successful in coming up with a vaccine.

Mike pointed out the risks in investing in small cap biotechnology stocks that had nothing going on.

But he recommended investing in Moderna (MRNA) even though it was a new company because he believed the company had substantial potential even if it was unable to produce a vaccine for the coronavirus.

Note that he did not recommend any other biotechnology stocks, so his hit-miss ratio was 100%.

So how has Moderna performed since March 2020?

It has soared by as much as 1500%. 

We have reserved access to these March 2020 webinars to Members and Research Clients.